<?xml version="1.0" encoding="UTF-8"?>

<Observation xmlns="http://hl7.org/fhir">
  <id value="TransurethralEnucleationDiagnosticConclusionGrouper"/>
  <meta>
    <profile value="https://www.medizininformatik-initiative.de/fhir/ext/modul-patho/StructureDefinition/mii-pr-patho-diagnostic-conclusion-grouper|2026.0.0"/>
  </meta>
  <text>
    <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Observation TransurethralEnucleationDiagnosticConclusionGrouper</b></p><a name="TransurethralEnucleationDiagnosticConclusionGrouper"> </a><a name="hcTransurethralEnucleationDiagnosticConclusionGrouper"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="https://simplifier.net/resolve?scope=de.medizininformatikinitiative.kerndatensatz.patho@2026.0.0&amp;canonical=https://www.medizininformatik-initiative.de/fhir/ext/modul-patho/StructureDefinition/mii-pr-patho-diagnostic-conclusion-grouper">MII PR Patho Diagnostic Conclusion Grouperversion: null2026.0.0)</a></p></div><p><b>basedOn</b>: <a href="ServiceRequest-TransurethralEnucleationReportRequest.html">ServiceRequest Simple prostatectomy (procedure)</a></p><p><b>status</b>: Final</p><p><b>category</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/observation-category laboratory}">Laboratory</span></p><p><b>code</b>: <span title="Codes:{http://loinc.org 22637-3}">Pathology report final diagnosis Narrative</span></p><p><b>subject</b>: <a href="Patient-Patient3.html">Klaus Becker  Male, DoB: 1958-11-10 ( http://example.hospital.de/patient-ids#PAT-2024-003)</a></p><p><b>effective</b>: 2024-05-12</p><p><b>performer</b>: <a href="Practitioner-PathologistPractitioner.html">Practitioner Maria Schneider </a></p><p><b>note</b>: By Practitioner/PathologistPractitioner @2024-05-12</p><blockquote><div><p>Diagnose: Azinäres Adenokarzinom der Prostata (ICD-O 8140/3) mit invasiven kribriformen Anteilen und intraduktaler Karzinomkomponente. Gleason-Score 4+5=9, ISUP-Gradgruppe 5 (WHO 2016). Prozentualer Anteil Gleasonmuster 4 und 5: 90%. Ausgedehnte Tumorinfiltration, ca. 60% des Prostatagewebes befallen. Extraprostatische Ausbreitung nachgewiesen. Samenblaseninfiltration nachgewiesen. Lymphovaskuläre Invasion nachgewiesen. Perineurale Infiltration nachgewiesen. Empfehlung: Staging-Untersuchungen und interdisziplinäre Tumorkonferenz.</p>
</div></blockquote><p><b>hasMember</b>: </p><ul><li><a href="Observation-TransurethralEnucleationHistologicalTypeICDO3.html">Observation Histology and Behavior ICD-O-3 Cancer</a></li><li><a href="Observation-TransurethralEnucleationMorphologyFreeText.html">Observation Histology type in Cancer specimen Narrative</a></li><li><a href="Observation-TransurethralEnucleationPrimaryGleasonPattern.html">Observation Gleason pattern.primary in Prostate tumor</a></li><li><a href="Observation-TransurethralEnucleationSecondaryGleasonPattern.html">Observation Gleason pattern.secondary in Prostate tumor</a></li><li><a href="Observation-TransurethralEnucleationGleasonScoreTotal.html">Observation Gleason score in Specimen Qualitative</a></li><li><a href="Observation-TransurethralEnucleationPercentageGleason45.html">Observation Prostate tumor area with Gleason pattern 4+5/Total tumor area</a></li><li><a href="Observation-TransurethralEnucleationGradingGroupISUP.html">Observation Prostate cancer grade group [Score] in Prostate tumor Qualitative</a></li><li><a href="Observation-TransurethralEnucleationIntraductalCarcinoma.html">Observation Non-infiltrating intraductal carcinoma (morphologic abnormality)</a></li><li><a href="Observation-TransurethralEnucleationInvasiveCribriformCarcinoma.html">Observation Invasive cribriform carcinoma (morphologic abnormality)</a></li><li><a href="Observation-TransurethralEnucleationProstaticTissueInvolved.html">Observation Tissue cores.positive.carcinoma in Tissue core</a></li><li><a href="Observation-TransurethralEnucleationExtraprostaticExtension.html">Observation Periprostatic fat invasion [Identifier] in Specimen by CAP cancer protocols</a></li><li><a href="Observation-TransurethralEnucleationSeminalVesicleInvasion.html">Observation Seminal vesicle invasion [Identifier] in Specimen by CAP cancer protocols</a></li><li><a href="Observation-TransurethralEnucleationLymphovascularInvasion.html">Observation Venous + Lymphatic small vessel invasion in Specimen by CAP cancer protocols</a></li><li><a href="Observation-TransurethralEnucleationPerineuralInfiltration.html">Observation Perineural invasion [Presence] in Cancer specimen</a></li></ul><p><b>derivedFrom</b>: <a href="QuestionnaireResponse-QuestionnaireResponseTransurethralEnucleation.html">Response to Questionnaire 'https://art-decor.org/fhir/Questionnaire/2.16.840.1.113883.3.1937.777.18.27.20--20250115134435' about '-&gt;Klaus Becker  Male, DoB: 1958-11-10 ( http://example.hospital.de/patient-ids#PAT-2024-003)'</a></p></div>
  </text>
  <basedOn>
    <reference value="ServiceRequest/TransurethralEnucleationReportRequest"/>
  </basedOn>
  <status value="final"/>
  <category>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/observation-category"/>
      <code value="laboratory"/>
    </coding>
  </category>
  <code>
    <coding>
      <system value="http://loinc.org"/>
      <code value="22637-3"/>
    </coding>
  </code>
  <subject>
    <reference value="Patient/Patient3"/>
  </subject>
  <effectiveDateTime value="2024-05-12"/>
  <performer>
    <reference value="Practitioner/PathologistPractitioner"/>
  </performer>
  <note>
    <authorReference>
      <reference value="Practitioner/PathologistPractitioner"/>
    </authorReference>
    <time value="2024-05-12"/>
    <text value="Diagnose: Azinäres Adenokarzinom der Prostata (ICD-O 8140/3) mit invasiven kribriformen Anteilen und intraduktaler Karzinomkomponente. Gleason-Score 4+5=9, ISUP-Gradgruppe 5 (WHO 2016). Prozentualer Anteil Gleasonmuster 4 und 5: 90%. Ausgedehnte Tumorinfiltration, ca. 60% des Prostatagewebes befallen. Extraprostatische Ausbreitung nachgewiesen. Samenblaseninfiltration nachgewiesen. Lymphovaskuläre Invasion nachgewiesen. Perineurale Infiltration nachgewiesen. Empfehlung: Staging-Untersuchungen und interdisziplinäre Tumorkonferenz."/>
  </note>
  <hasMember>
    <reference value="Observation/TransurethralEnucleationHistologicalTypeICDO3"/>
  </hasMember>
  <hasMember>
    <reference value="Observation/TransurethralEnucleationMorphologyFreeText"/>
  </hasMember>
  <hasMember>
    <reference value="Observation/TransurethralEnucleationPrimaryGleasonPattern"/>
  </hasMember>
  <hasMember>
    <reference value="Observation/TransurethralEnucleationSecondaryGleasonPattern"/>
  </hasMember>
  <hasMember>
    <reference value="Observation/TransurethralEnucleationGleasonScoreTotal"/>
  </hasMember>
  <hasMember>
    <reference value="Observation/TransurethralEnucleationPercentageGleason45"/>
  </hasMember>
  <hasMember>
    <reference value="Observation/TransurethralEnucleationGradingGroupISUP"/>
  </hasMember>
  <hasMember>
    <reference value="Observation/TransurethralEnucleationIntraductalCarcinoma"/>
  </hasMember>
  <hasMember>
    <reference value="Observation/TransurethralEnucleationInvasiveCribriformCarcinoma"/>
  </hasMember>
  <hasMember>
    <reference value="Observation/TransurethralEnucleationProstaticTissueInvolved"/>
  </hasMember>
  <hasMember>
    <reference value="Observation/TransurethralEnucleationExtraprostaticExtension"/>
  </hasMember>
  <hasMember>
    <reference value="Observation/TransurethralEnucleationSeminalVesicleInvasion"/>
  </hasMember>
  <hasMember>
    <reference value="Observation/TransurethralEnucleationLymphovascularInvasion"/>
  </hasMember>
  <hasMember>
    <reference value="Observation/TransurethralEnucleationPerineuralInfiltration"/>
  </hasMember>
  <derivedFrom>
    <reference value="QuestionnaireResponse/QuestionnaireResponseTransurethralEnucleation"/>
  </derivedFrom>
</Observation>